Omeros Q1 net loss $37.2M; cash extends into 2026 after $115.5M royalty deal

OMEROS CORP

2025-Q1 EPS reported -$0.63

Net loss $37.2M ($0.63/share) vs $33.7M ($0.54) in Q1 2023; loss from cont ops $43.9M vs $39.7M.
Cash + short-term investments $230.3M at Mar 31, up $58.5M from Dec 31; includes $115.5M from DRI royalty deal.
Sold DRI expanded OMIDRIA royalty: DRI gets all US royalties through 2031; Omeros retains ex-US & post-2031 global; potential milestones up to $27.5M each.
OMS906 Phase 2 PNH data at EHA June 15; Phase 3 start late 2024. Narsoplimab BLA resubmission timeline uncertain pending FDA.
Repurchased 3.2M shares for $11.9M in Q1.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OMEROS CORP reported the first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $37.2 million, or $0.63 per share, EPS $0.63 per share.

Period: the first quarter ended March 31, 2024
Net income: Net loss for the first quarter of 2024 was $37.2 million, or $0.63 per share
EPS: $0.63 per share
Result: reported results

Exact text from the filing

Omeros Corporation Reports First Quarter 2024 Financial Results

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

OMEROS CORP filing history →

Source: SEC EDGAR

accession 0001437749-24-017044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.